On Friday, May 22, the HIV Prevention Trials Network (HPTN) held a community webinar to discuss the preliminary results of HPTN 083, a global randomized, controlled, double-blinded study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) (Truvada) for pre-exposure prophylaxis (PrEP). The study showed that CAB LA lowered HIV incidence among cisgender men and transgender women who have sex with men. The sister study, HPTN 084 is the first study to compare the safety and efficacy of CAB LA to daily oral TDF/FTC for HIV PrEP among cisgender women. A panel discussion on HPTN 084’s importance to HIV prevention for cisgender women followed.
Moderator:
- Mitchell Warren, Executive Director, AVAC
Panelists:
- HPTN 083 Protocol Chair – Dr. Raphael Landovitz, UCLA Center for Clinical AIDS Research and Education (CARE)
- HPTN 083 Protocol Co-Chair – Dr. Beatriz Grinsztejn, National Institute of Infectious Diseases Evandro Chagas-Fiocruz
- HPTN 084 Protocol Chair – Dr. Sinead Delany-Moretlwe, Wits RHI, University of Witwatersrand
- HPTN 084 Protocol Co-Chair – Dr. Mina Hosseinipour, UNC Project Lilongwe